Pertussis Market Size was USD 5,395 Million in 2020 | Companies- Sanofi Pasteur, Mitsubishi Tanabe Pharma, GlaxosmithKline, ILiAD Biotechnologies, Serum Institute, Bilthoven, Vakzine Projekt Management GmbH (VPM), Cansino Bio, China National Biotec Group

The Pertussis market report provides current treatment practices, emerging drugs, Pertussis market share of the individual therapies, current and forecasted Pertussis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Pertussis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pertussis market.

Discover more about therapies set to grab major Pertussis Market Share @ Pertussis Market Size- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pertussis Market Report
• The total vaccine coverage population of Pertussis in the 7MM and China was 65,837,354 in 2020.
• The age-specific vaccine coverage case of Pertussis in the United States was estimated to be 20,058,055 in 2020.
• The Pertussis Market Size is expected to increase drastically owing to the launches of several potential emerging therapies during the forecast period (2023-2032).
• The leading Pertussis Companies include Sanofi Pasteur, Mitsubishi Tanabe Pharma, GlaxosmithKline, ILiAD Biotechnologies, Serum Institute, Bilthoven, Vakzine Projekt Management GmbH (VPM), Cansino Bio, China National Biotec Group and Beijing Institute of Biological Products, and others
• Promising Pertussis Pipeline Therapies include Adacel, Hexaxim/Hexyon/Hexacima, Vaxelis, Quadracel, Tetrabik/BK1310, Tribik/BK1301, Boostrix, BPZE1, BK1310/MT-2355, SIIPL Tdap, and others.
• BPZE1: ILiAD Biotechnologies is a technologically advanced live attenuated pertussis vaccine that contains genetic modifications to eliminate, attenuate or inactivate three different B. pertussis toxins that are inactivated pertussis toxin, deleted dermonecrotic toxin, and marked reduction in Tracheal toxin to protect against Bordetella pertussis nasal infection (colonization) and active disease through the induction of broad and sustained mucosal and systemic immunity. Based on the positive topline results from ILiADBiotechnologies on the Phase IIb trial of lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress, it met both primary endpoints of overall safety and induction of mucosal immunity. In January 2022, LiAD Biotechnologies announced that the USFDA has granted Fast Track designation to BPZE1 for active booster immunization against pertussis.
• BK1310/MT-2355: Mitsubishi Tanabe Pharma Corporation DPT-IPV-Hib (BK1310/ MT2355) vaccine is a 5-in-1 combination vaccine that protects against pertussis and other indications, including diphtheria, tetanus, and poliomyelitis, and prophylaxis of Hib infections in infants. This vaccine is co-developed with the Research Foundation for Microbial Diseases of Osaka University (Japan). The company has completed a Phase III trial in pertussis, and other indications include Diphtheria, Tetanus, Poliomyelitis, and Bacterial meningitis (In infants, in children, prevention) in Japan. The company plans to launch these five combined vaccines in Japan in FY2023.
• SIIPL Tdap: Serum Institute/Bilthoven/VPM is a combined vaccine for active immunization against tetanus, diphtheria and pertussis. The formulation contains reduced amounts of diphtheria and acellular pertussis antigens; therefore, it is indicated for booster immunization of adults, adolescents, and children. Vakzine Projekt Management GmbH (VPM) collaborates with the Serum Institute of India and Bilthoven Biologicals B.V. to develop the SIIPL Tdap vaccine. VPM is a development consulting firm for the biopharmaceutical industry. The vaccine has completed Phase III trial, and the Phase I trial was done in India to assess the safety and tolerability of SIIPL Tdap vaccine in healthy adult volunteers aged 18-45 years.

To explore more information on the latest breakthroughs in the Pertussis treatment landscape of the report, click here @ Pertussis Market Outlook- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pertussis Overview
Pertussis, literally meaning "a violent cough," and also known as whooping cough, or "the cough of 100 days," is an acute respiratory infection caused by Bordetella pertussis. First discovered in the Paris epidemic of 1578, pertussis is characterized by a paroxysmal cough lasting ≥2 weeks, an inspiratory whoop, posttussive emesis, and posttussive syncope.

Pertussis Epidemiology Segmentation in the 7MM
• Pertussis Age-Specific Vaccination Coverage

Download the report to understand which factors are driving Pertussis Epidemiology Trends @ Pertussis Epidemiological Insights- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pertussis Marketed Drugs

Adacel: Sanofi Pasteur
Adacel is a trivalent booster vaccine indicated for active immunization against pertussis, tetanus, and diphtheria. The vaccine is recommended from 4 years of age following primary immunization and is the first and only Tdap vaccine in the US. The vaccine is approved for a repeat dose in people 10-64 years of age 8 years or more after the first vaccination. It is available in 55 countries, including the US, Europe, Asia, and Latin America. It is administered as a single 0.5 mL intramuscular injection. For routine booster vaccination, the first dose of Adacel is administered 5 years or more after the last dose of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after vaccination with Tetanus and Diphtheria Toxoids Adsorbed (Td). A second dose of Adacel may be administered 8 years or more after the first dose with Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap). In June 2005, the US FDA approved the Adacel vaccine to address pertussis protection for people from 11 to 64 years of age. Adacel vaccine provides demonstrated immunogenicity against Pertussis tetanus and diphtheria and has a safety profile similar to that of the tetanus-diphtheria (Td) vaccine. In January 2019, the USFDA approved the expanded use of Adacel to include repeat vaccination to protect against pertussis, diphtheria, and tetanus. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.

Hexaxim/Hexyon/Hexacima: Sanofi Pasteur
Hexaxim (DTaP-IPV-HB-Hib) is a 6-in-1 pediatric vaccine indicated for primary and booster vaccination of infants and toddlers from 6 weeks of age against pertussis, tetanus, diphtheria, hepatitis B, poliomyelitis, and invasive diseases caused by Hemophilus influenza type b (Hib). The vaccine works by causing the body to produce its protection (antibodies) against bacteria and viruses.In 2019, the top 35 countries consumed 22 million hexavalent vaccines, representing 92% of the hexavalent vaccine global consumption. In April 2013, the vaccines division of Sanofi announced that the European Commission approved 6-in-1 pediatric vaccine Hexacima (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age. Hexyon is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against pertussis (whooping cough), tetanus, diphtheria, Hepatitis B, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b. The vaccine is commercialized under the brand name HexyonTM in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi.

Vaxelis: Sanofi Pasteur
Vaxelis is a PR5i hexavalent combination vaccine indicated for active immunization to prevent pertussis (whooping cough), diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. Vaxelis was developed as part of a US-based partnership established in 1991 between Merck and Sanofi Pasteur and draws upon both companies experience in the development, manufacturing, and marketing of individual and combination vaccines. It includes antigens for pertussis (whooping cough), diphtheria, tetanus, and poliomyelitis from Sanofi Pasteur and antigens for Haemophilus influenzae type b and hepatitis B from Merck. In June 2021, Vaxelis developed as part of a US-based partnership between Merck and the global vaccines business unit of Sanofi, is now available in the US indicated for active immunization to help prevent pertussis, diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to H. influenzae type b. In December 2018, US FDA has approved the Vaxelis vaccine for the treatment of acellular pertussis and other indications, which include Diphtheria, Tetanus Toxoid, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B for use in children from 6 weeks to 4 years of age (before the 5th birthday). In February 2016, the European Commission granted marketing authorization to Vaxelis (V419) for the treatment of pertussis with other indications, which include Diphtheria, Hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib) for use in infants and toddlers from the age of 6 weeks.

Boostrix: Glaxosmithkline (GSK)
Boostrix is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older. Boostrix is administered as a 0.5-mL intramuscular injection into the deltoid muscle of the upper arm. An initial dose of Boostrix is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td). Boostrix is one of the vaccines routinely recommended in the US for immunization of pregnant women. There have been no reported safety concerns in the US with the use of the vaccine in pregnancy. There is no evidence of risk to the pregnant woman or unborn child with inactivated vaccines like Boostrix IPV. The licence for Boostrix IPV allows for its use in pregnancy when clearly needed, and when the possible benefits outweigh the possible risks. In the UK, Boostrix IPV is similar to the 4-in-1 vaccine - the pre-school booster that is routinely given to children before they start school. Also, Boostrix is given during pregnancy in the UK. In July 2011, the US FDA approved the Boostrix vaccine to prevent tetanus, diphtheria, and pertussis in people ages 65 and older.

Quadracel: Sanofi Pasteur
Quadracel [Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine] is a sterile, uniform, cloudy, and white to off-white suspension of acellular pertussis and diphtheria and tetanus toxoids vaccine adsorbed separately on aluminum phosphate combined with inactivated poliomyelitis vaccine types 1, 2 and 3 and suspended in water for injection. The acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN, and FIM). A single dose of Quadracel vaccine is approved for use in children 4-6 years of age as a fifth dose in diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received four doses of Pentacel or Daptacel vaccine. The vaccine provides these two vaccines in a single shot. In March 2015, the vaccines division of Sanofi announced that the US FDA had approved the use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against pertussis, diphtheria, tetanus, and poliomyelitis in children 4-6 years of age.

Tetrabik/BK1310: Mitsubishi Tanabe pharma
Tetrabik is a combined prophylactic vaccine comprising a B. Pertussis protective antigen, adsorbed diphtheria toxoid, tetanus toxoid, and inactivated Savin types 1, 2, and 3 of poliovirus as active ingredients that prevent pertussis, diphtheria, acute poliomyelitis (polio), and tetanus. Tetrabik was developed in collaboration with the Research Foundation for Microbial Diseases of Osaka University and Biken. Tetrabik is administered as primary immunization series for children, which consist of three doses of 0.5 mL each given by subcutaneous injection at intervals of at least 3 weeks, and afterwards, the usual booster dose for children is a single 0.5 mL dose given by subcutaneous injection that is given at least 6 months after the primary immunization. In July 2012, the Ministry of Health, Labour and Welfare (MHLW) concluded that the Tetrabik may be approved. This result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council.

Pertussis Emerging Vaccines

BPZE1: ILiAD Biotechnologies
BPZE1 is a technologically advanced live attenuated pertussis vaccine that contains genetic modifications to eliminate, attenuate or inactivate three different B. pertussis toxins that are inactivated pertussis toxin, deleted dermonecrotic toxin, and marked reduction in Tracheal toxin to protect against Bordetella pertussis nasal infection (colonization) and active disease through the induction of broad and sustained mucosal and systemic immunity. BPZE1 is currently being developed as a booster vaccine, with future development investigating its application as a primary vaccination in infants. The BPZE1 strain was developed at the Institute Pasteur de Lille and Inserm by a team of scientists led by Dr. Camille Locht. It is the most advanced next-generation pertussis vaccine which has completed two Phase II clinical trials.

BK1310/MT-2355: Mitsubishi Tanabe pharma
DPT-IPV-Hib (BK1310/ MT-2355) vaccine is a 5-in-1 combination vaccine that protects against pertussis and other indications, including diphtheria, tetanus, and poliomyelitis, and prophylaxis of Hib infections in infants. This vaccine is co-developed with the Research Foundation for Microbial Diseases of Osaka University (Japan). The company has completed a Phase III trial in pertussis, and other indications include Diphtheria, Tetanus, Poliomyelitis, and Bacterial meningitis (In infants, in children, prevention) in Japan. The company plans to launch these five combined vaccines in Japan in FY2023.

SIIPL Tdap: Serum Institute/Bilthoven/VPM
SIIPL Tdap, manufactured by Serum Institute of India and Bilthoven Biologicals, is a combined vaccine for active immunization against tetanus, diphtheria and pertussis. The formulation contains reduced amounts of diphtheria and acellular pertussis antigens; therefore, it is indicated for booster immunization of adults, adolescents, and children. Vakzine Projekt Management GmbH (VPM) collaborates with the Serum Institute of India and Bilthoven Biologicals B.V. to develop the SIIPL Tdap vaccine. VPM is a development consulting firm for the biopharmaceutical industry. The vaccine has completed Phase III trial, and the Phase I trial was done in India to assess the safety and tolerability of SIIPL Tdap vaccine in healthy adult volunteers aged 18-45 years.

DTcP Infant and Booster: Cansino Bio
DTcP Infant vaccine is for infants (below 2 years old), addresses the weaker protection preventing pertussis after primary vaccination. DTcP Booster is a vaccine also being developed by the company that addresses the weaker protection preventing pertussis after primary vaccination, designed for children (4-6 years old). The vaccines are currently being developed in China, and they are in Phase II of development.

Pertussis Market Outlook
Pertussis, or whooping cough, is a contagious, infectious disease that mainly affects children and is caused by Bordetella pertussis. This disease spares no age group, though infants have the highest casualties. At the ground level, diagnosing pertussis remains a major challenge for clinicians. Variability in definitions, an evolving clinical spectrum from prior vaccination and lack of classic symptoms complicate the presentation. Early treatment of pertussis is essential. The earlier a person, especially an infant, starts treatment, the better. If a patient starts treatment for pertussis early in the course of illness, during the first 1-2 weeks before coughing paroxysms occur, symptoms may be lessened.

To know more about Pertussis Therapies options, visit @ Pertussis Therapeutics Market- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pertussis Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Pertussis Companies- Sanofi Pasteur, Mitsubishi Tanabe Pharma, GlaxosmithKline, ILiAD Biotechnologies, Serum Institute, Bilthoven, Vakzine Projekt Management GmbH (VPM), Cansino Bio, China National Biotec Group and Beijing Institute of Biological Products, and others
• Pertussis Pipeline Therapies- Adacel, Hexaxim/Hexyon/Hexacima, Vaxelis, Quadracel, Tetrabik/BK1310, Tribik/BK1301, Boostrix, BPZE1, BK1310/MT-2355, SIIPL Tdap, and others.
• Pertussis Market Dynamics: Pertussis Market Drivers and Barriers

Discover more about Pertussis Drugs in development @ Pertussis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Pertussis
3. Competitive Intelligence Analysis for Pertussis
4. Pertussis: Market Overview at a Glance
5. Pertussis: Disease Background and Overview
6. Patient Journey
7. Pertussis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Pertussis Unmet Needs
10. Key Endpoints of Pertussis Treatment
11. Pertussis Marketed Products
12. Pertussis Emerging Therapies
13. Pertussis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Pertussis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Learn more about the Pertussis Pipeline Therapies in clinical trials @ Pertussis SWOT Analysis, Unmet Needs, Reimbursement, and Patient Journey- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.